Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era

Cancer

Volumn 120, Issue 13, 2014, Pages 2050-2059

  Kushner, Brian H ^a   Modak, Shakeel ^a   Kramer, Kim ^a   Laquaglia, Michael P ^a   Yataghene, Karima ^a   Basu, Ellen M ^a   Roberts, Stephen S ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

contemporary therapy; induction; MYCN; neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYCN GENE; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR GROWTH;

CONTEMPORARY THERAPY; INDUCTION; MYCN; NEUROBLASTOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84902540178     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28687     Document Type: Article

References (47)

1. Burkhardt-Hammer T, Spix C, Brenner H, et al. Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in Germany. Med Pediatr Oncol. 2002; 39: 156-162.
2. Schroeder H, Wacher J, Larsson H, et al. Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study. Br J Cancer. 2009; 100: 853-857.
3. Haupt R, Garaventa A, Gambini C, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol. 2010; 28: 2331-2338.
4. Castel V, Canete A, Navarro S, et al. Outcome of high-risk neuroblastoma using a dose-intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol. 2001; 37: 537-542.
5. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases survival rates of patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002; 24: 613-621.
6. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than 1 year at diagnosis: comparable results with 3 consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol. 2003; 21: 1592-1601.
7. Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in 5 consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003; 197: 11-17.
8. Pearson A, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9: 247-256.
9. Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008; 51: 747-753.
10. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol. 2009; 27: 1007-1013.
11. Park JR, Villablanca JG, London WB, et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009; 52: 44-50.
12. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24: 2891-2896.
13. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005; 6: 649-658.
14. Canete A, Gerrard M, Rubie H, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European neuroblastoma experience. J Clin Oncol. 2009; 27: 1014-1019.
15. Sung KW, Lee SH, Yoo KH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant. 2007; 40: 37-45.
16. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomized phase 3 trial. Lancet Oncol. 2013; 14: 999-1008.
17. Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009; 27: 289-297.
18. Moroz V, Machin D, Faldum A, et al. Changes over 3 decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group project. Eur J Cancer. 2011; 47: 561-571.
19. Modak S, Kushner BH, LaQuaglia MP, Kramer, K, Cheung N-KV,. Management and outcome of INSS stage 3 neuroblastoma. Eur J Cancer. 2009; 45: 90-98.
20. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung N-KV,. Reduction from 7 to 5 cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004; 22: 4888-4892.
21. Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011; 29: 4351-4357.
22. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose (21 Gy) radiotherapy for high-risk neuroblastoma following intensive chemotherapy and surgery. J Clin Oncol. 2001; 19: 2821-2828.
23. Yu A, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010; 363: 1324-1334.
24. Cheung N-KV, Cheung IY, Kushner BH, Ostrovnaya I, Kramer K, Modak S,. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor and 13-cis-retinoic acid is effective against chemoresistant marrow MRD among high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012; 30: 3264-3270.
25. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007; 25: 1054-1060.
26. Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003; 98: 2488-2494.
27. Simon T, Langler A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma: results of a phase-II trial. J Cancer Res Clin Oncol. 2007; 133: 653-661.
28. Kushner BH, Kramer K, Modak S, Cheung N-KV,. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006; 24: 5271-5276.
29. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009; 100: 1471-1482.
30. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11: 1466-1477.
31. Kushner BH, Kramer K, Modak S, Qin L-X, Cheung N-KV,. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010; 116: 3054-3060.
32. Kushner BH, Kramer K, Modak S, Yataghene K, Cheung N-KV,. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer. 2010; 47: 84-89.
33. Kushner BH, Kramer K, Modak S, Cheung N-KV,. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer. 2011; 56: 403-408.
34. Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung N-KV,. ICE for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2013; 119: 665-671.
35. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001; 19: 3463-3469.
36. Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-Oncol. 2010; 97: 409-418.
37. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D,. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004; 26: 227-232.
38. Santana V, Furman WL, McGregor LM, Billups CA,. Disease control intervals in high-risk neuroblastoma. Cancer. 2008; 112: 2796-2801.
39. Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009; 45: 2835-2842.
40. London WB, Castel V, Monclair T, et al. Clinical and biological features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J Clin Oncol. 2011; 29: 3286-3292.
41. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B,. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011; 56: 578-583.
42. Kushner BH, Kramer K, Cheung N-KV,. Chronic neuroblastoma: indolent stage 4 disease in children. Cancer. 2002; 95: 1366-1375.
43. Cheung N-KV, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012; 307: 1062-1071.
44. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents. The Italian experience. Cancer. 2006; 106: 1409-1417.
45. Taggart DR, London WB, Schmidt ML, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011; 29: 4358-4364.
46. Cole KA, Maris JM,. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res. 2012; 18: 2423-2428.
47. Kushner BH, Kramer K, Modak S, Cheung N-KV,. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009; 27: 1041-1046.